JP2019519533A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519533A5
JP2019519533A5 JP2018561938A JP2018561938A JP2019519533A5 JP 2019519533 A5 JP2019519533 A5 JP 2019519533A5 JP 2018561938 A JP2018561938 A JP 2018561938A JP 2018561938 A JP2018561938 A JP 2018561938A JP 2019519533 A5 JP2019519533 A5 JP 2019519533A5
Authority
JP
Japan
Prior art keywords
composition
yap
subject
gls1
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018561938A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519533A (ja
JP7079937B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/034420 external-priority patent/WO2017205595A1/en
Publication of JP2019519533A publication Critical patent/JP2019519533A/ja
Publication of JP2019519533A5 publication Critical patent/JP2019519533A5/ja
Priority to JP2022079875A priority Critical patent/JP7411967B2/ja
Application granted granted Critical
Publication of JP7079937B2 publication Critical patent/JP7079937B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018561938A 2016-05-26 2017-05-25 肺血管疾患を治療するための組成物および方法 Active JP7079937B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022079875A JP7411967B2 (ja) 2016-05-26 2022-05-16 肺血管疾患を治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341848P 2016-05-26 2016-05-26
US62/341,848 2016-05-26
PCT/US2017/034420 WO2017205595A1 (en) 2016-05-26 2017-05-25 Compositions and methods for treating pulmonary vascular disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022079875A Division JP7411967B2 (ja) 2016-05-26 2022-05-16 肺血管疾患を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019519533A JP2019519533A (ja) 2019-07-11
JP2019519533A5 true JP2019519533A5 (enExample) 2020-06-25
JP7079937B2 JP7079937B2 (ja) 2022-06-03

Family

ID=60412630

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018561938A Active JP7079937B2 (ja) 2016-05-26 2017-05-25 肺血管疾患を治療するための組成物および方法
JP2022079875A Active JP7411967B2 (ja) 2016-05-26 2022-05-16 肺血管疾患を治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022079875A Active JP7411967B2 (ja) 2016-05-26 2022-05-16 肺血管疾患を治療するための組成物および方法

Country Status (7)

Country Link
US (2) US10925869B2 (enExample)
EP (2) EP3463574B1 (enExample)
JP (2) JP7079937B2 (enExample)
KR (2) KR20220120711A (enExample)
CN (2) CN115192719B (enExample)
AU (1) AU2017270092B2 (enExample)
WO (1) WO2017205595A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10925869B2 (en) 2016-05-26 2021-02-23 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for treating pulmonary vascular disease
EP3713569B1 (en) * 2017-11-22 2024-03-13 University of Pittsburgh- Of the Commonwealth System of Higher Education Therapeutic particle comprising a yap1/wwrt1 inhibiting agent and the glutaminase inhibiting agent 2-cyclopropyl-n-[5-(4-{ [5-(2-phenylacetamido)-1,3,4-thiadiazol-2-yl]amino}piperidin-1-yl)-1,3,4-thiadiazol-2-yl] acetamide and use thereof for treating a pulmonary disease
JP7156856B2 (ja) * 2018-08-21 2022-10-19 国立大学法人富山大学 抗肥満剤
EP3690110B1 (en) 2019-02-01 2021-06-02 LG Electronics Inc. Laundry treating apparatus
EP3690108B1 (en) 2019-02-01 2021-05-12 LG Electronics Inc. Laundry treating apparatus
EP3690109B1 (en) 2019-02-01 2021-05-05 LG Electronics Inc. Laundry treating apparatus
US20220233535A1 (en) * 2019-05-05 2022-07-28 Georgetown University Use of inhibitors of yap/taz for the treatment of cancer
EP3980072A4 (en) * 2019-06-05 2023-06-14 University of Georgia Research Foundation COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION RELATED TO HUMAN IMMUNE DEFICIENCY VIRUS
JP7514508B2 (ja) * 2020-05-19 2024-07-11 国立大学法人鳥取大学 胆道がん治療薬
US12653785B2 (en) * 2020-05-21 2026-06-16 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for administering a YAP1/WWRT1 inhibiting composition and a GLS1 inhibiting composition
CN116421591A (zh) * 2023-05-10 2023-07-14 哈尔滨医科大学大庆分校 Ldha抑制剂在制备治疗肺动脉高压的药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5798345A (en) 1990-09-21 1998-08-25 Bone Care International, Inc. Method of inhibiting the hyperproliferation of malignant cells
US5707608A (en) 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
US20090202540A1 (en) * 2008-02-11 2009-08-13 Auspex Pharmaceuticals, Inc. Substituted oxazaphosphorines
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES
KR100963435B1 (ko) 2008-06-19 2010-06-17 한국과학기술연구원 서방형 약물전달 및 조직재생용 덮인 다공성 생분해성고분자 미립구의 제조 방법
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
WO2015138902A1 (en) 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US20170226507A1 (en) 2014-05-05 2017-08-10 The Brigham And Women's Hospital, Inc. Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases
US20160058759A1 (en) * 2014-07-03 2016-03-03 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
WO2016007647A1 (en) 2014-07-09 2016-01-14 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
CN106794233B (zh) * 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
US10517844B2 (en) * 2014-11-13 2019-12-31 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
WO2016130889A1 (en) 2015-02-12 2016-08-18 The Johns Hopkins University Inhibition of yap for breaking tumor immune tolerance
WO2017004310A1 (en) 2015-07-02 2017-01-05 Children's Medical Center Corporation Triplet-triplet annihilation-based upconversion
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
US10925869B2 (en) * 2016-05-26 2021-02-23 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for treating pulmonary vascular disease
EP3713569B1 (en) * 2017-11-22 2024-03-13 University of Pittsburgh- Of the Commonwealth System of Higher Education Therapeutic particle comprising a yap1/wwrt1 inhibiting agent and the glutaminase inhibiting agent 2-cyclopropyl-n-[5-(4-{ [5-(2-phenylacetamido)-1,3,4-thiadiazol-2-yl]amino}piperidin-1-yl)-1,3,4-thiadiazol-2-yl] acetamide and use thereof for treating a pulmonary disease

Similar Documents

Publication Publication Date Title
SA521422270B1 (ar) Apol1 مثبطات لـ وطرق لاستخدامها
CO2021010415A2 (es) Inhibidor jak y método de preparación del mismo
JP2019516739A5 (enExample)
BR112018010650A2 (pt) pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal
JP2016518337A5 (enExample)
JP2020523327A5 (enExample)
EP3999121A4 (en) TREATMENT/PREVENTION OF DISEASE BY INHIBITION OF LING COMPLEX
JP2015024998A5 (enExample)
JP2017141277A5 (enExample)
JP2019507781A5 (enExample)
JP2017530163A5 (enExample)
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
JP2020502047A5 (enExample)
CN114072404A (zh) Ret选择性抑制剂及其制备方法和用途
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
MX2018004043A (es) Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados.
CN111989095A (zh) 预防或治疗肿瘤疗法副作用的方法
JPWO2023195530A5 (enExample)
JP2019511550A5 (enExample)
EA201692470A1 (ru) Фармацевтические комбинации
JP2019519593A5 (enExample)
JP2017505809A5 (enExample)
JP2018524306A5 (enExample)
JP2016532632A5 (enExample)
JP2016531846A5 (enExample)